Adavivint (SM04690)

Catalog No.S8761 Batch:S876101

Print

Technical Data

Formula

C29H24FN7O

Molecular Weight 505.55 CAS No. 1467093-03-3
Solubility (25°C)* In vitro DMSO 30 mg/mL (59.34 mM)
Water Insoluble
Ethanol Insoluble
In vivo (Add solvents to the product individually and in order)
Clear solution
5%DMSO 40%PEG300 5%Tween80 50%ddH2O
0.75mg/ml Taking the 1 mL working solution as an example, add 50 μL of 15 mg/ml clarified DMSO stock solution to 400 μL of PEG300, mix evenly to clarify it; add 50 μL of Tween80 to the above system, mix evenly to clarify; then continue to add 500 μL of ddH2O to adjust the volume to 1 mL. The mixed solution should be used immediately for optimal results. 
Clear solution
5% DMSO 95% Corn oil
0.18mg/ml Taking the 1 mL working solution as an example, add 50 μL of 3.6 mg/ml clear DMSO stock solution to 950 μL of corn oil and mix evenly. The mixed solution should be used immediately for optimal results. 
* <1 mg/ml means slightly soluble or insoluble.
* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.
* Room temperature shipping (Stability testing shows this product can be shipped without any cooling measures.)

Preparing Stock Solutions

Biological Activity

Description Adavivint (SM04690,Lorecivivint) is a potent and specific inhibitor of canonical Wnt signaling with an EC50 of 19.5 nM for inhibiting the TCF/LEF reporter. It is ∼150- to 500-fold more potent than the other known Wnt inhibitors across multiple cellular assays.
Targets
Wnt [1]
In vitro

Bone-marrow-derived hMSCs (CD29+, CD44+ CD166+ CD105+ CD45-), treated with SM04690, show a dose-dependent decrease in the expression of Wnt pathway genes (ASCL1, LEF1, TCF7L2, TCF7, C-262 MYC and AXIN2). M04690 also inhibits the expression of AXIN2, TCF7 and LEF1 in hMSCs and AXIN2 and LGR5 in IEC6 (intestinal stem cells sensitive to Wnt activation) when the Wnt pathway is selectively activated using either Wnt3a or a GSK3β inhibitor, CHIR-99021. SM04690 has minimal effects on the non-canonical Wnt pathway and the BMP pathway. SM04690 protects chondrocytes from catabolic breakdown in vitro[1].

In vivo

Intra-articular injection of SM04690 promotes cartilage growth and improves joint health in a rat model of knee osteoarthritis. It decreases cartilage breakdown in vivo[1].

Protocol (from reference)

Cell Assay:

[1]

  • Cell lines

    SW480 cells and hMSCs

  • Concentrations

    10, 30 and 100 nM

  • Incubation Time

    48 h

  • Method

    --

Animal Study:

[1]

  • Animal Models

    Sprague-Dawley (SD) rats (12 weeks old, male)

  • Dosages

    0.3μg in 50μl

  • Administration

    intra-articular injection

Selleck's Adavivint (SM04690) has been cited by 8 publications

Pharmacological inhibition of CLK2 activates YAP by promoting alternative splicing of AMOTL2 [ Elife, 2023, 12RP88508] PubMed: 38126343
Canonical Wnt Pathway Is Involved in Chemoresistance and Cell Cycle Arrest Induction in Colon Cancer Cell Line Spheroids [ Int J Mol Sci, 2023, 24(6)5252] PubMed: 36982333
Canonical Wnt Pathway Is Involved in Chemoresistance and Cell Cycle Arrest Induction in Colon Cancer Cell Line Spheroids [ Int J Mol Sci, 2023, 24(6)5252] PubMed: 36982333
"Pharmacological inhibition of CLK2 activates YAP by promoting alternative splicing of AMOTL2" [ bioRxiv, 2023, 2023.04.19.537449] PubMed: 37131806
β-catenin regulates HIV latency and modulates HIV reactivation [ PLoS Pathog, 2022, 18(3):e1010354] PubMed: 35255110
Glycyrrhizic acid alters the hyperoxidative stress-induced differentiation commitment of MSCs by activating the Wnt/β-catenin pathway to prevent SONFH [ Food Funct, 2022, 10.1039/d2fo02337g] PubMed: 36541285
Engineering osteoarthritic cartilage model through differentiating senescent human mesenchymal stem cells for testing disease-modifying drugs [ Sci China Life Sci, 2021, 10.1007/s11427-021-1933-7] PubMed: 34109475
Inhibiting Wnt/beta-catenin in CTNNB1-mutated endometrial cancer [ Mol Carcinog, 2021, 10.1002/mc.23308] PubMed: 34038589

RETURN POLICY
Selleck Chemical’s Unconditional Return Policy ensures a smooth online shopping experience for our customers. If you are in any way unsatisfied with your purchase, you may return any item(s) within 7 days of receiving it. In the event of product quality issues, either protocol related or product related problems, you may return any item(s) within 365 days from the original purchase date. Please follow the instructions below when returning products.

SHIPPING AND STORAGE
Selleck products are transported at room temperature. If you receive the product at room temperature, please rest assured, the Selleck Quality Inspection Department has conducted experiments to verify that the normal temperature placement of one month will not affect the biological activity of powder products. After collecting, please store the product according to the requirements described in the datasheet. Most Selleck products are stable under the recommended conditions.

NOT FOR HUMAN, VETERINARY DIAGNOSTIC OR THERAPEUTIC USE.